TIANJIN DEV (00882): Tianjin Lisheng Pharmaceutical's net profit attributable to shareholders for the first three quarters was RMB78.51 million, down 78.82% year-on-year.
TIANJIN DEV (00882) announced the results of Tianjin Lisheng Pharmaceutical for the nine months ended September 30, 2026, with total operating revenue of RMB888 million, down 11.84% year-on-year; net profit attributable to owners of the parent company of RMB78.51 million, down 78.82% year-on-year; and basic earnings per share of RMB0.25.
TIANJIN DEV (00882) announced the results of Tianjin Lisheng Pharmaceutical for the nine months ended September 30, 2026, with total operating revenue of RMB888 million, down 11.84% year-on-year; net profit attributable to owners of the parent company of RMB78.51 million, down 78.82% year-on-year; and basic earnings per share of RMB0.25.
Related Articles
RMB13.29 million! YIDU TECH (02158) wins bid for the First Affiliated Hospital of Chongqing Medical University's next-generation big data platform project, continuing to expand its medical data foundation layout in Grade 3A hospitals.
POLYFAIR HLDGS (08532) suspended trading from the morning of October 26.
MAGNUSCONCORDIA (01172) subsidiary and Sichuan Juxinghua Trading separately entered into sale and purchase agreements for the purchase and sale of properties
RMB13.29 million! YIDU TECH (02158) wins bid for the First Affiliated Hospital of Chongqing Medical University's next-generation big data platform project, continuing to expand its medical data foundation layout in Grade 3A hospitals.
POLYFAIR HLDGS (08532) suspended trading from the morning of October 26.
MAGNUSCONCORDIA (01172) subsidiary and Sichuan Juxinghua Trading separately entered into sale and purchase agreements for the purchase and sale of properties
